UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549
FORM 8-K

CURRENT REPORT Pursuant
to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 18, 2008

Integrated BioPharma, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-28876

22-2407475

(Commission File Number)

(IRS Employer Identification No.)

    225 Long Avenue

Hillside, New Jersey

 

07205

(Address of Principal Executive Offices)

(Zip Code)

(973) 926-0816

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

|_|     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_|     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_|     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_|     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01     Other Items

      Integrated BioPharma, Inc. (the “Company”) announced on August 18, 2008 that the distribution of the Company’s interest in iBioPharma, Inc. (formerly InB:Biotechnologies, Inc.) (“iBioPharma”) became effective on August 18, 2008 (the “Distribution Date").

 

      A copy of the press release issued by the Company is attached as Exhibit 99.1 hereto.

Item 9.01     Financial Reports and Exhibits.
 
      (d)     Exhibits.

Exhibit No.      Description

99.1     Press Release dated August 18, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRATED BIOPHARMA, Inc.

Date:   August 19, 2008                 By: /s/ Dina L. Masi          

Name: Dina L. Masi

Title: Chief Financial Officer